CA2668311A1 - Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog - Google Patents

Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog Download PDF

Info

Publication number
CA2668311A1
CA2668311A1 CA002668311A CA2668311A CA2668311A1 CA 2668311 A1 CA2668311 A1 CA 2668311A1 CA 002668311 A CA002668311 A CA 002668311A CA 2668311 A CA2668311 A CA 2668311A CA 2668311 A1 CA2668311 A1 CA 2668311A1
Authority
CA
Canada
Prior art keywords
modulator
hydroxypyridine
ultraviolet light
enhancing
photodamage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002668311A
Other languages
French (fr)
Other versions
CA2668311C (en
Inventor
Georg T. Wondrak
Michael J. Roberts
Moonsun Kim
Myron K. Jacobson
Elaine L. Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arizona Board of Regents of University of Arizona
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2668311A1 publication Critical patent/CA2668311A1/en
Application granted granted Critical
Publication of CA2668311C publication Critical patent/CA2668311C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Radiation-Therapy Devices (AREA)
  • Photovoltaic Devices (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods for modulating photodamage via the use of collagen derived molecules which either enhance or inhibit damage caused by ultraviolet light.

Claims (6)

1. Use of a photodamage modulator for enhancing photodamage caused by ultraviolet light in a subject in need thereof, wherein said modulator is :

.cndot. a modulator which has a structure consisting of an N-alkyl-3-hydroxypyridine or salt thereof, wherein the alkyl moiety is 2-20 carbon atoms, .cndot. vitamin B6, .cndot. pyridinoline, or .cndot. 3-hydroxypyridine.
2. The use of claim 1, wherein said modulator is collagen derived.
3. The use of claim 1, wherein said modulator is N-alkyl-3-hydroxypyridine or salt thereof.
4. The use of claim 1, wherein said alkyl moiety is an ethyl group.
5. The use of claim 1, wherein said modulator is connected to a carrier molecule.
6. The use of claim 1, wherein said modulator is vitamin B6, pyridinoline, or hydroxypyridine.
CA2668311A 2002-04-19 2003-04-17 Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog Expired - Fee Related CA2668311C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37403302P 2002-04-19 2002-04-19
US60/374,033 2002-04-19
CA2482320A CA2482320C (en) 2002-04-19 2003-04-17 Methods for modulating phototoxicity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2482320A Division CA2482320C (en) 2002-04-19 2003-04-17 Methods for modulating phototoxicity

Publications (2)

Publication Number Publication Date
CA2668311A1 true CA2668311A1 (en) 2003-10-30
CA2668311C CA2668311C (en) 2011-08-02

Family

ID=29251125

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2482320A Expired - Fee Related CA2482320C (en) 2002-04-19 2003-04-17 Methods for modulating phototoxicity
CA2668311A Expired - Fee Related CA2668311C (en) 2002-04-19 2003-04-17 Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2482320A Expired - Fee Related CA2482320C (en) 2002-04-19 2003-04-17 Methods for modulating phototoxicity

Country Status (17)

Country Link
US (3) US6992071B2 (en)
EP (1) EP1496891B1 (en)
JP (2) JP4527405B2 (en)
CN (1) CN1298321C (en)
AT (1) ATE516802T1 (en)
AU (1) AU2003234119B2 (en)
CA (2) CA2482320C (en)
CY (1) CY1112194T1 (en)
DK (1) DK1496891T3 (en)
ES (1) ES2367258T3 (en)
HK (1) HK1077761B (en)
IL (2) IL164560A0 (en)
MX (1) MXPA04010228A (en)
NZ (1) NZ535982A (en)
PT (1) PT1496891E (en)
RU (1) RU2301800C2 (en)
WO (1) WO2003088909A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1298321C (en) * 2002-04-19 2007-02-07 亚利桑那大学董事会 Methods for modulating phototoxicity
WO2009112360A1 (en) * 2008-03-10 2009-09-17 Basf Se Encapsulated phase change materials in seed coatings
JP5727364B2 (en) * 2009-03-30 2015-06-03 株式会社 資生堂 UV damage reducing composition

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310461A (en) * 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US6309440B1 (en) * 1998-08-25 2001-10-30 Thomas T. Yamashita Method and composition for promoting and controlling growth of plants
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
JPH0797322A (en) * 1993-09-29 1995-04-11 Shiseido Co Ltd Singlet oxygen elimination agent
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same
US6013250A (en) * 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
JP2961074B2 (en) * 1995-09-06 1999-10-12 明治製菓株式会社 Neovascular occlusive agents for photochemotherapy
JPH09249567A (en) * 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd Medicinal composition
WO1997041826A1 (en) * 1996-05-07 1997-11-13 Thomas Jefferson University Use of tempol in the prevention of photoaging
US20010056085A1 (en) * 1996-07-09 2001-12-27 Avner Ramu Methods of using vesicant drug formulations
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
EP0987266A4 (en) * 1997-03-31 2000-07-26 Wakamoto Pharma Co Ltd Biphenyl derivatives and medicinal compositions
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
FR2775595B1 (en) * 1998-03-09 2000-05-05 Seppic Sa SYNERGISTIC COMPOSITION COMPRISING A LIPOAMINOACID STRUCTURE COMPOUND AND MENUPHAR EXTRACT
JPH11255715A (en) * 1998-03-13 1999-09-21 Kao Corp N,n-di-substituted aniline derivative
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
FR2792650B1 (en) * 1999-04-20 2003-02-28 Oreal EQUIVALENT OF ELDERLY SKIN, ITS PREPARATION METHOD AND ITS USE
WO2000066599A1 (en) * 1999-04-30 2000-11-09 Oberthuer Walter Antioxidative vitamin b6 analogs
US6333344B1 (en) * 1999-05-05 2001-12-25 Merck & Co. Prolines as antimicrobial agents
US20020006394A1 (en) * 2000-02-11 2002-01-17 Redmond Robert W. Photochemical tissue bonding
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
EP1304323A4 (en) * 2000-07-19 2005-01-12 Kyowa Hakko Kogyo Kk Preventives or remedies for atopic dermatitis
JP2002128651A (en) * 2000-10-25 2002-05-09 Kose Corp Photoaging inhibitor and skin care preparation characterized by comprising the same
IL157042A0 (en) * 2001-02-05 2004-02-08 Buchanan Leonard Stephen Multi-tapered dental files
CN1298321C (en) * 2002-04-19 2007-02-07 亚利桑那大学董事会 Methods for modulating phototoxicity
DE102005000868A1 (en) * 2004-10-15 2006-04-20 Henkel Kgaa Compositions with inhibitors of prostaglandin and / or leukotriene synthesis in combination with stimulants of the release of cutaneous neuromediators

Also Published As

Publication number Publication date
CA2668311C (en) 2011-08-02
CA2482320C (en) 2010-02-09
ATE516802T1 (en) 2011-08-15
HK1077761B (en) 2007-05-25
DK1496891T3 (en) 2011-10-24
JP4527405B2 (en) 2010-08-18
CN1298321C (en) 2007-02-07
EP1496891A4 (en) 2009-10-21
AU2003234119A1 (en) 2003-11-03
IL164560A0 (en) 2005-12-18
JP2005534625A (en) 2005-11-17
RU2301800C2 (en) 2007-06-27
CA2482320A1 (en) 2003-10-30
EP1496891A2 (en) 2005-01-19
CY1112194T1 (en) 2015-12-09
AU2003234119B2 (en) 2007-02-08
JP5244150B2 (en) 2013-07-24
NZ535982A (en) 2006-10-27
PT1496891E (en) 2011-09-02
WO2003088909A3 (en) 2004-02-12
WO2003088909A2 (en) 2003-10-30
US20030223941A1 (en) 2003-12-04
JP2010163461A (en) 2010-07-29
RU2004133322A (en) 2005-08-10
EP1496891B1 (en) 2011-07-20
IL203968A0 (en) 2011-07-31
MXPA04010228A (en) 2005-06-08
US6992071B2 (en) 2006-01-31
ES2367258T3 (en) 2011-10-31
CN1646121A (en) 2005-07-27
IL203968A (en) 2013-02-28
US20060009416A1 (en) 2006-01-12
US7226937B2 (en) 2007-06-05
US20050042188A1 (en) 2005-02-24
HK1077761A1 (en) 2006-02-24

Similar Documents

Publication Publication Date Title
AU2003292657A1 (en) Skin lightening composition
HK1100511A1 (en) Bicycloester derivative
RS53599B1 (en) Pyridone derivatives for modulating stress-activated protein kinase system
AU2006304874A8 (en) Pyrimidinones as casein kinase II (CK2) modulators
WO2007019255A3 (en) Salts of vildagliptin
EP2172472A3 (en) Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor
MX2007004763A (en) (biphenyl) carboxylic acids and derivatives thereof.
NO20043174L (en) Pyrido [2,1-a] isoquinoline derivatives as DPP-IV inhibitors
IL165502A0 (en) Method for preparing 3-halo-4,5-dihydro-1h-pyrazoles
HK1081199A1 (en) Process and intermediates for the preparation of (1r,2s,5s)-6,6-dimethyl-3- azabicyclo [3,1,0] hexane-2-carboxylates or salts thereof
WO2001017973A3 (en) Novel herbicides
AU2003286083A1 (en) Method to improve interferometric signatures by coherent point scatterers
HK1053473A1 (en) Inhibitors of alpha-l beta-2 mediated cell adhesion.
DK1467706T3 (en) Dermal application system for aminolevulinic acid derivatives
DK1534707T5 (en) Substituted 2,4-dihydropyrrolo [3,4-b] quinolin-9-one derivatives useful as phosphodiesterase inhibitors
WO2006124865A3 (en) Biaryls derivatives useful as modulators of ion channels
AU2003268687A1 (en) Novel salt of 2-acylaminothiazole derivative
BR0014990A (en) Ranphthalazinone tetrahydrothiopyrane derivatives as pde4 inhibitors
CA2668311A1 (en) Enhancing photodamage caused by ultraviolet light using a 3-hydroxypyridine analog
EA200600316A1 (en) Derivatives 3
WO2003029254A1 (en) Process for preparation of tricyclic compounds
DK1531158T3 (en) Lipid A topical, especially cosmetic, composition comprising it
DE69703115D1 (en) Intermediates to produce 2-imidazolin-5one derivatives.
BRPI0411186A (en) transparent liquid soap composition and process for preparing it
AU2001282238A1 (en) Dihydroporphyrin derivatives and their uses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220301

MKLA Lapsed

Effective date: 20200831